Skip to main content
logo
PharmaCyte Biotech, Inc. (PMCB)
NASDAQ: PMCB · Real-Time Price · USD
0.4913
+0.0106 (2.21%)
At close: Sep 3, 2026, 4:00 PM EDT
0.5000
+0.0087 (1.77%)
Pre-market: Sep 4, 2026, 8:37 AM EDT

PharmaCyte Biotech Income Statement

Millions USD. Fiscal year is May - Apr.
Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Apr '26 Apr '25 Apr '24 Apr '23 Apr '22
Selling, General & Admin
4.913.946.115.993.7
Research & Development
0.390.440.410.470.69
Operating Expenses
5.34.386.526.464.39
Operating Income
-5.3-4.38-6.52-6.46-4.39
Interest Expense
-----0
Interest & Investment Income
1.111.423.41.940.16
Other Non Operating Income (Expenses)
-7.749.115.450.2-0
EBT Excluding Unusual Items
-11.936.152.33-4.32-4.24
Gain (Loss) on Sale of Investments
-6.0626.53---
Asset Writedown
-1.55--2--
Legal Settlements
0.11-2.02---
Pretax Income
-19.4230.660.33-4.32-4.24
Net Income
-19.4230.660.33-4.32-4.24
Preferred Dividends & Other Adjustments
3.787.2917.57--
Net Income to Common
-23.2123.36-17.24-4.32-4.24
Net Income Growth
-----
Shares Outstanding (Basic)
87101916
Shares Outstanding (Diluted)
87101916
Shares Change
14.31%-23.50%-50.84%25.56%971.73%
EPS (Basic)
-2.773.19-1.80-0.22-0.27
EPS (Diluted)
-2.773.19-1.80-0.22-0.27
EPS Growth
-----

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Apr '26 Apr '25 Apr '24 Apr '23 Apr '22
EBIT
-5.3-4.38-6.52-6.46-4.39
SEC Filings: 10-K · 10-Q